Truveta Research study published in JAMA Internal Medicine compares tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
08. Juli 2024 11:16 ET | Truveta
BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
Truveta Research found that patients with overweight or obesity taking tirzepatide (Mounjaro) experienced a greater percentage change in body weight than those taking semaglutide (Ozempic) for weight loss.
Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss
27. November 2023 09:00 ET | Truveta
BELLEVUE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...